CRVS Projected Dividend Yield
Corvus Pharmaceuticals Inc ( NASDAQ : CRVS )Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of immune modulator product candidates to treat solid cancers, T-cell lymphomas, autoimmune diseases and infectious diseases. Co.'s lead product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Co.'s next product candidate, CPI-818, is a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T-cell lymphomas. Co.'s third product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine. 20 YEAR PERFORMANCE RESULTS |
CRVS Dividend History Detail CRVS Dividend News CRVS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |